Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:
“Pancreatic cancer has long been the disease where immunotherapy doesn’t work.
That assumption may be breaking.
In this piece, I discuss how autogene cevumeran – an individualized mRNA neoantigen vaccine – is showing that we can generate an immune response where none existed before, with evidence of durable CD8+ T-cell memory even in PDAC.
This isn’t about incremental improvement.
It’s about redefining what’s biologically possible.
Thank you Cancer Netwrk for the feature.”
Title: Autogene Cevumeran and The Future of Personalized Cancer Vaccines
Authors: Yan Leyfman
Read the Full Article.
Other articles featuring Yan Leyfman on OncoDaily.